Heart monitor maker HeartBeam Q3 net loss widens on increased R&D expenses

Heartbeam

13/11/2025 21:10

Overview

HeartBeam Q3 net loss widens to $5.3 mln, with increased R&D expenses, vs loss of $5 mln year ago

Company anticipates FDA clearance for 12-lead ECG software by year-end

HeartBeam partners with HeartNexus for on-demand cardiologist reviews

Outlook

HeartBeam anticipates FDA clearance for ECG software by Q4 2025

Company plans to initiate commercialization post-FDA clearance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.15
Q3 Net Income
-$5.26 mln
Q3 Basic EPS
-$0.15
Q3 Income From Operations
-$5.29 mln
Q3 Operating Expenses
$5.29 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Heartbeam Inc is $4.00, about 58.3% above its November 12 closing price of $1.67

Press Release: ID:nBw6B18dSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)